A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-06

AUTHORS

Marc C. Chamberlain, Sean Grimm, Surasak Phuphanich, Larry Recht, Jay Z. Zhu, Lyndon Kim, Steve Rosenfeld, Camilo E. Fadul, Brain Tumor Investigational Consortium (BTIC)

ABSTRACT

Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM. More... »

PAGES

335-343

References to SciGraph publications

  • 2012-11. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme in JOURNAL OF NEURO-ONCOLOGY
  • 2005-06. Disrupting tumour blood vessels in NATURE REVIEWS CANCER
  • 2010-01. Salvage therapy with single agent bevacizumab for recurrent glioblastoma in JOURNAL OF NEURO-ONCOLOGY
  • 2006-07. Mechanisms of angiogenesis in gliomas in JOURNAL OF NEURO-ONCOLOGY
  • 2006-08. Drug penetration in solid tumours in NATURE REVIEWS CANCER
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y

    DOI

    http://dx.doi.org/10.1007/s11060-014-1437-y

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1031583661

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/24740196


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angiogenesis Inhibitors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bevacizumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Brain Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease-Free Survival", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glioblastoma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Recurrence, Local", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prospective Studies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Quinazolines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Young Adult", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "name": [
                "Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, 825 Eastlake Ave E, MS: G4-940, 98109, Seattle, WA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chamberlain", 
            "givenName": "Marc C.", 
            "id": "sg:person.01326261166.36", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Northwestern University", 
              "id": "https://www.grid.ac/institutes/grid.16753.36", 
              "name": [
                "Department of Neurology, Northwestern University, 710\u00a0N Lake Shore Drive, Abbott Hall, Room 1110, 60611, Chicago, IL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Grimm", 
            "givenName": "Sean", 
            "id": "sg:person.0576221411.84", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576221411.84"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cedars-Sinai Medical Center", 
              "id": "https://www.grid.ac/institutes/grid.50956.3f", 
              "name": [
                "Cedars Sinai Medical Center, 8631\u00a0W 3rd St, Ste 410-E, 90048, Los Angeles, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Phuphanich", 
            "givenName": "Surasak", 
            "id": "sg:person.01346246457.67", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Lucile Packard Children's Hospital", 
              "id": "https://www.grid.ac/institutes/grid.414123.1", 
              "name": [
                "Stanford University, 875 Blake Wilbur Dr Rm 2221, 943042205, Palo Alto, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Recht", 
            "givenName": "Larry", 
            "id": "sg:person.01275010460.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275010460.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Tufts University", 
              "id": "https://www.grid.ac/institutes/grid.429997.8", 
              "name": [
                "Tufts University, 750 Washington St, # 833, 02111, Boston, MA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhu", 
            "givenName": "Jay Z.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "name": [
                "Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kim", 
            "givenName": "Lyndon", 
            "id": "sg:person.0635633346.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635633346.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Cleveland Clinic", 
              "id": "https://www.grid.ac/institutes/grid.239578.2", 
              "name": [
                "Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, 9500 Euclid Avenue, Mailcode: NB40, 44195, Cleveland, OH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rosenfeld", 
            "givenName": "Steve", 
            "id": "sg:person.010674622762.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674622762.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Dartmouth\u2013Hitchcock Medical Center", 
              "id": "https://www.grid.ac/institutes/grid.413480.a", 
              "name": [
                "Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, 03756, Lebanon, NH, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Fadul", 
            "givenName": "Camilo E.", 
            "id": "sg:person.01356122202.32", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356122202.32"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Brain Tumor Investigational Consortium (BTIC)", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s11060-005-9097-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001104504", 
              "https://doi.org/10.1007/s11060-005-9097-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-005-9097-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001104504", 
              "https://doi.org/10.1007/s11060-005-9097-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/neuonc/not151", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003959313"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2011.39.3934", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009031942"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/0008-5472.can-07-0127", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010238020"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2008.16.3055", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010751135"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2009-006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011570339"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-09-3106", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014254065"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmc.2006.10.020", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014613992"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1893", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017162057", 
              "https://doi.org/10.1038/nrc1893"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1893", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017162057", 
              "https://doi.org/10.1038/nrc1893"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1628", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017276673", 
              "https://doi.org/10.1038/nrc1628"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1586/ern.11.30", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018407035"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2005.04.8801", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021574047"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-012-0964-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030739430", 
              "https://doi.org/10.1007/s11060-012-0964-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.bmcl.2010.01.155", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033299281"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.2217/cns.12.5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037403239"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-10-0516", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038106726"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-009-9957-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040541619", 
              "https://doi.org/10.1007/s11060-009-9957-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11060-009-9957-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040541619", 
              "https://doi.org/10.1007/s11060-009-9957-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2012.41.9242", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042233716"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2008.19.8721", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042965400"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2009.26.3541", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043187529"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmra0708126", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043717119"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2007-062", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046098276"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2011.36.1311", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047945986"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1056/nejmoa043330", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052112015"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm801315b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055956088"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1021/jm801315b", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1055956088"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1212/01.wnl.0000304121.57857.38", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064350042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1215/15228517-2006-025", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064414261"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1999.17.8.2572", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1074549881"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077005540", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.1990.8.7.1277", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1078716995"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2010.28.15_suppl.8531", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083944555"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2014-06", 
        "datePublishedReg": "2014-06-01", 
        "description": "Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab na\u00efve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab na\u00efve or refractory recurrent GBM.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1007/s11060-014-1437-y", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2438816", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1094205", 
            "issn": [
              "0167-594X", 
              "1573-7373"
            ], 
            "name": "Journal of Neuro-Oncology", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "118"
          }
        ], 
        "name": "A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)", 
        "pagination": "335-343", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "96753a3a68bb18df00615a6990c89c3504169041f2af19d1428f7e49b030bea6"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "24740196"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "8309335"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s11060-014-1437-y"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1031583661"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s11060-014-1437-y", 
          "https://app.dimensions.ai/details/publication/pub.1031583661"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-10T15:05", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000532.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "http://link.springer.com/10.1007%2Fs11060-014-1437-y"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-014-1437-y'


     

    This table displays all metadata directly associated to this object as RDF triples.

    311 TRIPLES      21 PREDICATES      78 URIs      39 LITERALS      27 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s11060-014-1437-y schema:about N03f5652812924cd49f306d532b5c23f3
    2 N1c7c5fb321da44849bb315761be4421d
    3 N2211659dd79f4850b4e1aa576dc45201
    4 N2550ce0ae1de4c00a1700d904db84b29
    5 N3038642eb850474ab27bb4af9b94c7a9
    6 N41ed147ddae7483db64323293b3f1323
    7 N4a002188d83b411594301fa5522acfd8
    8 N672caf2086444007bbcb24dd36765f4e
    9 N7111e092e64a4b20850b93a93a592b78
    10 N869d5796c52d4ee29f5da1ca79333056
    11 N90f137a3d877441b8facf7efd9e1022b
    12 N951f77f73ff549f6a5442d7cc1dc8942
    13 Na2fc75cdb51544e8ae1ba7ec9b7129d6
    14 Nc34c74057d0644a59ae212a4eb5a6107
    15 Nd9d8e03e54be465c8966b222f38787c0
    16 Ne5661ee76e5e40a6a4941267ccfce6d0
    17 Nf8cd81d34eb344c8bd6b3996134370ef
    18 Nfe4600c4033843d7b3e8355ade0cdc18
    19 anzsrc-for:11
    20 anzsrc-for:1103
    21 schema:author Nf8876d80a826400590d3807ff13b4ff1
    22 schema:citation sg:pub.10.1007/s11060-005-9097-6
    23 sg:pub.10.1007/s11060-009-9957-6
    24 sg:pub.10.1007/s11060-012-0964-7
    25 sg:pub.10.1038/nrc1628
    26 sg:pub.10.1038/nrc1893
    27 https://app.dimensions.ai/details/publication/pub.1077005540
    28 https://doi.org/10.1016/j.bmc.2006.10.020
    29 https://doi.org/10.1016/j.bmcl.2010.01.155
    30 https://doi.org/10.1021/jm801315b
    31 https://doi.org/10.1056/nejmoa043330
    32 https://doi.org/10.1056/nejmra0708126
    33 https://doi.org/10.1093/neuonc/not151
    34 https://doi.org/10.1158/0008-5472.can-07-0127
    35 https://doi.org/10.1158/1078-0432.ccr-09-3106
    36 https://doi.org/10.1158/1535-7163.mct-10-0516
    37 https://doi.org/10.1200/jco.1990.8.7.1277
    38 https://doi.org/10.1200/jco.1999.17.8.2572
    39 https://doi.org/10.1200/jco.2005.04.8801
    40 https://doi.org/10.1200/jco.2008.16.3055
    41 https://doi.org/10.1200/jco.2008.19.8721
    42 https://doi.org/10.1200/jco.2009.26.3541
    43 https://doi.org/10.1200/jco.2010.28.15_suppl.8531
    44 https://doi.org/10.1200/jco.2011.36.1311
    45 https://doi.org/10.1200/jco.2011.39.3934
    46 https://doi.org/10.1200/jco.2012.41.9242
    47 https://doi.org/10.1212/01.wnl.0000304121.57857.38
    48 https://doi.org/10.1215/15228517-2006-025
    49 https://doi.org/10.1215/15228517-2007-062
    50 https://doi.org/10.1215/15228517-2009-006
    51 https://doi.org/10.1586/ern.11.30
    52 https://doi.org/10.2217/cns.12.5
    53 schema:datePublished 2014-06
    54 schema:datePublishedReg 2014-06-01
    55 schema:description Treatment options are limited for recurrent glioblastoma (GBM). Verubulin is a microtubule destabilizer and vascular disrupting agent that achieve high brain concentration relative to plasma in animals. Adults with recurrent GBM who failed prior standard therapy were eligible. The primary endpoint was 1-month progression-free survival (PFS-1) for bevacizumab refractory (Group 2) and 6-month progression-free survival (PFS-6) for bevacizumab naïve patients (Group 1). Verubulin was administered at 3.3 mg/m(2) as a 2-h intravenous infusion once weekly for 3 consecutive weeks in a 4-week cycle. The planned sample size was 34 subjects per cohort. 56 patients (37 men, 19 women) were enrolled, 31 in Group 1 and 25 in Group 2. The PFS-6 for Group 1 was 14% and the PFS-1 for Group 2 was 20%. Median survival from onset of treatment was 9.5 months in Group 1 and 3.4 months in Group 2. Best overall response was partial response (n = 3; 10% in Group 1; n = 1; 4.2% in Group 2) and stable disease (n = 7; 23% in Group 1; n = 5; 21% in Group 2). In Group 1, 38.7% of patients experienced a serious adverse event; however only 3.2% were potentially attributable to study drug. In Group 2, 44% of patients experienced a serious adverse event although none were attributable to study drug. Accrual was terminated early for futility. Single agent verubulin, in this dose and schedule, is well tolerated, associated with moderate but tolerable toxicity but has limited activity in either bevacizumab naïve or refractory recurrent GBM.
    56 schema:genre research_article
    57 schema:inLanguage en
    58 schema:isAccessibleForFree false
    59 schema:isPartOf N1a8c0ac61de14196abbf1cf6712cdc39
    60 N48941039cce347868bc74db39b7b7e34
    61 sg:journal.1094205
    62 schema:name A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the brain tumor investigational consortium (BTIC)
    63 schema:pagination 335-343
    64 schema:productId N184b2dcfcdc64a91946dd96b3911787c
    65 N26c39d4773104758b1a68aa4f5edd465
    66 N310555bfbe2b45848f4121cd07624dcd
    67 Nb1629be6b0c345dab4445dd8771726fc
    68 Ne8f69c067f03409b96447bdbf6e45d76
    69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031583661
    70 https://doi.org/10.1007/s11060-014-1437-y
    71 schema:sdDatePublished 2019-04-10T15:05
    72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    73 schema:sdPublisher N8d564a6d04f343b2aaefdb1c6a511fd7
    74 schema:url http://link.springer.com/10.1007%2Fs11060-014-1437-y
    75 sgo:license sg:explorer/license/
    76 sgo:sdDataset articles
    77 rdf:type schema:ScholarlyArticle
    78 N03f5652812924cd49f306d532b5c23f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    79 schema:name Glioblastoma
    80 rdf:type schema:DefinedTerm
    81 N10b6af63c56f41d68d3d1fd9e53b8c0c schema:familyName Brain Tumor Investigational Consortium (BTIC)
    82 rdf:type schema:Person
    83 N184b2dcfcdc64a91946dd96b3911787c schema:name doi
    84 schema:value 10.1007/s11060-014-1437-y
    85 rdf:type schema:PropertyValue
    86 N1a8c0ac61de14196abbf1cf6712cdc39 schema:volumeNumber 118
    87 rdf:type schema:PublicationVolume
    88 N1c7c5fb321da44849bb315761be4421d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name Prospective Studies
    90 rdf:type schema:DefinedTerm
    91 N2211659dd79f4850b4e1aa576dc45201 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    92 schema:name Aged
    93 rdf:type schema:DefinedTerm
    94 N2550ce0ae1de4c00a1700d904db84b29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    95 schema:name Antineoplastic Agents
    96 rdf:type schema:DefinedTerm
    97 N26c39d4773104758b1a68aa4f5edd465 schema:name pubmed_id
    98 schema:value 24740196
    99 rdf:type schema:PropertyValue
    100 N2e9d2791692c4e0eb0af32e77fe0dfeb rdf:first Nf822bc91fe224415803d5046d54d6e6e
    101 rdf:rest Nf70c0d718c6d45eb9f45b8245e072492
    102 N3038642eb850474ab27bb4af9b94c7a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Angiogenesis Inhibitors
    104 rdf:type schema:DefinedTerm
    105 N310555bfbe2b45848f4121cd07624dcd schema:name dimensions_id
    106 schema:value pub.1031583661
    107 rdf:type schema:PropertyValue
    108 N34fc49feeffc407b9ad9f7eb15235446 rdf:first N10b6af63c56f41d68d3d1fd9e53b8c0c
    109 rdf:rest rdf:nil
    110 N41ed147ddae7483db64323293b3f1323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Neoplasm Recurrence, Local
    112 rdf:type schema:DefinedTerm
    113 N48941039cce347868bc74db39b7b7e34 schema:issueNumber 2
    114 rdf:type schema:PublicationIssue
    115 N4a002188d83b411594301fa5522acfd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Humans
    117 rdf:type schema:DefinedTerm
    118 N4d4698c214c04f2fad44095d89261bd4 rdf:first sg:person.0576221411.84
    119 rdf:rest Nba78b1afbd9144a9bf59b9e728e71720
    120 N5daf0d9778be4a34b3372b9ea76701c9 rdf:first sg:person.01275010460.24
    121 rdf:rest N2e9d2791692c4e0eb0af32e77fe0dfeb
    122 N672caf2086444007bbcb24dd36765f4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Brain Neoplasms
    124 rdf:type schema:DefinedTerm
    125 N704e396e6579473f9a0f2ddc6e9f3f51 rdf:first sg:person.01356122202.32
    126 rdf:rest N34fc49feeffc407b9ad9f7eb15235446
    127 N7111e092e64a4b20850b93a93a592b78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Young Adult
    129 rdf:type schema:DefinedTerm
    130 N869d5796c52d4ee29f5da1ca79333056 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Treatment Outcome
    132 rdf:type schema:DefinedTerm
    133 N8d564a6d04f343b2aaefdb1c6a511fd7 schema:name Springer Nature - SN SciGraph project
    134 rdf:type schema:Organization
    135 N8e54629a05874ab082f23b3db6efea2b rdf:first sg:person.010674622762.80
    136 rdf:rest N704e396e6579473f9a0f2ddc6e9f3f51
    137 N90f137a3d877441b8facf7efd9e1022b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Disease-Free Survival
    139 rdf:type schema:DefinedTerm
    140 N951f77f73ff549f6a5442d7cc1dc8942 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Quinazolines
    142 rdf:type schema:DefinedTerm
    143 N95aab62f13144f108e2ef1801a116a98 schema:name Jefferson University, 900 Walnut Street, Suite 200, 19107, Philadelphia, PA, USA
    144 rdf:type schema:Organization
    145 Na2fc75cdb51544e8ae1ba7ec9b7129d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    146 schema:name Female
    147 rdf:type schema:DefinedTerm
    148 Nb1629be6b0c345dab4445dd8771726fc schema:name nlm_unique_id
    149 schema:value 8309335
    150 rdf:type schema:PropertyValue
    151 Nba78b1afbd9144a9bf59b9e728e71720 rdf:first sg:person.01346246457.67
    152 rdf:rest N5daf0d9778be4a34b3372b9ea76701c9
    153 Nc34c74057d0644a59ae212a4eb5a6107 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name Middle Aged
    155 rdf:type schema:DefinedTerm
    156 Nd9d8e03e54be465c8966b222f38787c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Antibodies, Monoclonal, Humanized
    158 rdf:type schema:DefinedTerm
    159 Ne5661ee76e5e40a6a4941267ccfce6d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Male
    161 rdf:type schema:DefinedTerm
    162 Ne8f69c067f03409b96447bdbf6e45d76 schema:name readcube_id
    163 schema:value 96753a3a68bb18df00615a6990c89c3504169041f2af19d1428f7e49b030bea6
    164 rdf:type schema:PropertyValue
    165 Nef6e0074124744c08fdb2a172c3753e3 schema:name Seattle Cancer Care Alliance, Fred Hutchinson Cancer Center, University of Washington, 825 Eastlake Ave E, MS: G4-940, 98109, Seattle, WA, USA
    166 rdf:type schema:Organization
    167 Nf70c0d718c6d45eb9f45b8245e072492 rdf:first sg:person.0635633346.28
    168 rdf:rest N8e54629a05874ab082f23b3db6efea2b
    169 Nf822bc91fe224415803d5046d54d6e6e schema:affiliation https://www.grid.ac/institutes/grid.429997.8
    170 schema:familyName Zhu
    171 schema:givenName Jay Z.
    172 rdf:type schema:Person
    173 Nf8876d80a826400590d3807ff13b4ff1 rdf:first sg:person.01326261166.36
    174 rdf:rest N4d4698c214c04f2fad44095d89261bd4
    175 Nf8cd81d34eb344c8bd6b3996134370ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Adult
    177 rdf:type schema:DefinedTerm
    178 Nfe4600c4033843d7b3e8355ade0cdc18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Bevacizumab
    180 rdf:type schema:DefinedTerm
    181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    182 schema:name Medical and Health Sciences
    183 rdf:type schema:DefinedTerm
    184 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    185 schema:name Clinical Sciences
    186 rdf:type schema:DefinedTerm
    187 sg:grant.2438816 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-014-1437-y
    188 rdf:type schema:MonetaryGrant
    189 sg:journal.1094205 schema:issn 0167-594X
    190 1573-7373
    191 schema:name Journal of Neuro-Oncology
    192 rdf:type schema:Periodical
    193 sg:person.010674622762.80 schema:affiliation https://www.grid.ac/institutes/grid.239578.2
    194 schema:familyName Rosenfeld
    195 schema:givenName Steve
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010674622762.80
    197 rdf:type schema:Person
    198 sg:person.01275010460.24 schema:affiliation https://www.grid.ac/institutes/grid.414123.1
    199 schema:familyName Recht
    200 schema:givenName Larry
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275010460.24
    202 rdf:type schema:Person
    203 sg:person.01326261166.36 schema:affiliation Nef6e0074124744c08fdb2a172c3753e3
    204 schema:familyName Chamberlain
    205 schema:givenName Marc C.
    206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
    207 rdf:type schema:Person
    208 sg:person.01346246457.67 schema:affiliation https://www.grid.ac/institutes/grid.50956.3f
    209 schema:familyName Phuphanich
    210 schema:givenName Surasak
    211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67
    212 rdf:type schema:Person
    213 sg:person.01356122202.32 schema:affiliation https://www.grid.ac/institutes/grid.413480.a
    214 schema:familyName Fadul
    215 schema:givenName Camilo E.
    216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356122202.32
    217 rdf:type schema:Person
    218 sg:person.0576221411.84 schema:affiliation https://www.grid.ac/institutes/grid.16753.36
    219 schema:familyName Grimm
    220 schema:givenName Sean
    221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576221411.84
    222 rdf:type schema:Person
    223 sg:person.0635633346.28 schema:affiliation N95aab62f13144f108e2ef1801a116a98
    224 schema:familyName Kim
    225 schema:givenName Lyndon
    226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635633346.28
    227 rdf:type schema:Person
    228 sg:pub.10.1007/s11060-005-9097-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001104504
    229 https://doi.org/10.1007/s11060-005-9097-6
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1007/s11060-009-9957-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040541619
    232 https://doi.org/10.1007/s11060-009-9957-6
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1007/s11060-012-0964-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030739430
    235 https://doi.org/10.1007/s11060-012-0964-7
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1038/nrc1628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017276673
    238 https://doi.org/10.1038/nrc1628
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1038/nrc1893 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017162057
    241 https://doi.org/10.1038/nrc1893
    242 rdf:type schema:CreativeWork
    243 https://app.dimensions.ai/details/publication/pub.1077005540 schema:CreativeWork
    244 https://doi.org/10.1016/j.bmc.2006.10.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014613992
    245 rdf:type schema:CreativeWork
    246 https://doi.org/10.1016/j.bmcl.2010.01.155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033299281
    247 rdf:type schema:CreativeWork
    248 https://doi.org/10.1021/jm801315b schema:sameAs https://app.dimensions.ai/details/publication/pub.1055956088
    249 rdf:type schema:CreativeWork
    250 https://doi.org/10.1056/nejmoa043330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052112015
    251 rdf:type schema:CreativeWork
    252 https://doi.org/10.1056/nejmra0708126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043717119
    253 rdf:type schema:CreativeWork
    254 https://doi.org/10.1093/neuonc/not151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003959313
    255 rdf:type schema:CreativeWork
    256 https://doi.org/10.1158/0008-5472.can-07-0127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010238020
    257 rdf:type schema:CreativeWork
    258 https://doi.org/10.1158/1078-0432.ccr-09-3106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014254065
    259 rdf:type schema:CreativeWork
    260 https://doi.org/10.1158/1535-7163.mct-10-0516 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038106726
    261 rdf:type schema:CreativeWork
    262 https://doi.org/10.1200/jco.1990.8.7.1277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078716995
    263 rdf:type schema:CreativeWork
    264 https://doi.org/10.1200/jco.1999.17.8.2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549881
    265 rdf:type schema:CreativeWork
    266 https://doi.org/10.1200/jco.2005.04.8801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021574047
    267 rdf:type schema:CreativeWork
    268 https://doi.org/10.1200/jco.2008.16.3055 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010751135
    269 rdf:type schema:CreativeWork
    270 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
    271 rdf:type schema:CreativeWork
    272 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
    273 rdf:type schema:CreativeWork
    274 https://doi.org/10.1200/jco.2010.28.15_suppl.8531 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083944555
    275 rdf:type schema:CreativeWork
    276 https://doi.org/10.1200/jco.2011.36.1311 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047945986
    277 rdf:type schema:CreativeWork
    278 https://doi.org/10.1200/jco.2011.39.3934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009031942
    279 rdf:type schema:CreativeWork
    280 https://doi.org/10.1200/jco.2012.41.9242 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042233716
    281 rdf:type schema:CreativeWork
    282 https://doi.org/10.1212/01.wnl.0000304121.57857.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064350042
    283 rdf:type schema:CreativeWork
    284 https://doi.org/10.1215/15228517-2006-025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064414261
    285 rdf:type schema:CreativeWork
    286 https://doi.org/10.1215/15228517-2007-062 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046098276
    287 rdf:type schema:CreativeWork
    288 https://doi.org/10.1215/15228517-2009-006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011570339
    289 rdf:type schema:CreativeWork
    290 https://doi.org/10.1586/ern.11.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018407035
    291 rdf:type schema:CreativeWork
    292 https://doi.org/10.2217/cns.12.5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037403239
    293 rdf:type schema:CreativeWork
    294 https://www.grid.ac/institutes/grid.16753.36 schema:alternateName Northwestern University
    295 schema:name Department of Neurology, Northwestern University, 710 N Lake Shore Drive, Abbott Hall, Room 1110, 60611, Chicago, IL, USA
    296 rdf:type schema:Organization
    297 https://www.grid.ac/institutes/grid.239578.2 schema:alternateName Cleveland Clinic
    298 schema:name Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, 9500 Euclid Avenue, Mailcode: NB40, 44195, Cleveland, OH, USA
    299 rdf:type schema:Organization
    300 https://www.grid.ac/institutes/grid.413480.a schema:alternateName Dartmouth–Hitchcock Medical Center
    301 schema:name Hematology/Oncology Section, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, 03756, Lebanon, NH, USA
    302 rdf:type schema:Organization
    303 https://www.grid.ac/institutes/grid.414123.1 schema:alternateName Lucile Packard Children's Hospital
    304 schema:name Stanford University, 875 Blake Wilbur Dr Rm 2221, 943042205, Palo Alto, CA, USA
    305 rdf:type schema:Organization
    306 https://www.grid.ac/institutes/grid.429997.8 schema:alternateName Tufts University
    307 schema:name Tufts University, 750 Washington St, # 833, 02111, Boston, MA, USA
    308 rdf:type schema:Organization
    309 https://www.grid.ac/institutes/grid.50956.3f schema:alternateName Cedars-Sinai Medical Center
    310 schema:name Cedars Sinai Medical Center, 8631 W 3rd St, Ste 410-E, 90048, Los Angeles, CA, USA
    311 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...